A Phase 3 Clinical Trial of I124-evuzamitide to Diagnose Cardiac Amyloidosis

30 August 2026 (13:45 - 14:00)

Organised by:

Video

Slides

Sign in for access options

About the speaker

Doctor Sharmila Dorbala

Brigham and Women's Hospital, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail

Efficacy and safety of transthyretin gene silencer eplontersen in patients with transthyretin amyloid cardiomyopathy receiving stabiliser therapy in the CARDIO-TTRansform trial

Doctor P. Garcia-Pavia (Majadahonda, ES)

Presentation thumbnail

Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy

Doctor Y. Hamatani (Boston, US)

Presentation thumbnail

A Meta-Analysis of Gene Silencer Therapy in ATTR-CM

Doctor J. Gillmore (Greater London, GB)

Presentation thumbnail

Effect of anselamimab on cardiac structure and function in patients with light chain amyloidosis: The CARES trials

Doctor X. Wang (Boston, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

30 August 2026 13:45 CET

You may be interested in

Webinar

Diagnosing and treating cardiac amyloidosis

17 November 2022

Congress Presentation

Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE study

31 August 2025

Congress Presentation

functional capacity assessment of cardiac amyloidosis patients before treatment and rehabilitation

13 June 2025

Congress Presentation

Longitudinal evaluation of cardiac and extracardiac amyloid load in patients with AL and ATTR amyloidosis, measured by 124I-AT-01 PET/CT imaging

25 August 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources